Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04878497CT.gov Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty | — | Unknown | — | — | — |
NCT04437303CT.gov Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI) | — | Completed | — | — | — |
NCT04808934CT.gov NOAC Portuguese Real World Study | — | Withdrawn | — | — | — |
NCT04045665CT.gov Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | — | Recruiting | — | — | — |
NCT03119116CT.gov Use of Direct Oral Anticoagulants in UK | — | Completed | — | — | — |
NCT00262600CT.gov Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dabigatran (this asset) | Brigham and Women's Hospital | Approved | BB · 66 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Aspirin | China National Center for Cardiovascular Diseases | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Dabigatran
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Atrial Fibrillation | — | P4 | BBB · 79 |
| Atrial Flutter | — | P4 | BBB · 78 |
| Thrombotic Disease | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dabigatran in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dabigatran-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →